Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisPRNewsWire • 05/16/24
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndromePRNewsWire • 05/16/24
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/07/24
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/24
Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 EarningsZacks Investment Research • 05/06/24
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromePRNewsWire • 04/07/24
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingPRNewsWire • 03/25/24
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHPRNewsWire • 03/13/24
Ionis announces new chief global product strategy officer to lead next phase of commercial growthPRNewsWire • 02/29/24